The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti ...

GSA Capital Partners LLP cut its stake in Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 81.9% in the third quarter, according ...